IBM researchers use deep learning, neural networks to screen for diabetic retinopathy with 86% accuracy

Out of the 422 million people around the world living with diabetes, one in three of them will develop diabetic retinopathy (DR), a common condition that can lead to permanent blindness if left untreated. While early detection and treatment can dramatically reduce that risk, a third of people with diabetes have never even been screened for DR, as many are living in low-income, medically underserved areas that make the much-needed clinical intervention impossible.

But new research from IBM suggests technology can rise up to fill those healthcare gaps. Using a mix of deep learning, convolutional neural networks and visual analytics technology based on 35,000 images accessed via EyePACs, the IBM technology learned to identify lesions and other markers of damage to the retina’s blood vessels, collectively assessing the presence and severity of disease. In just 20 seconds, the method was successful in classifying DR severity with 86 percent accuracy, suggesting doctors and clinicians could use the technology to have a better idea of how the disease progresses as well as identify effective treatment methods.

While it’s still early days for the technology, researchers are excited for the possibility of using IBM’s method to replace or augment traditional DR screening and treatment processes, which currently require a comprehensive in-person visit with a specialist.

“A comprehensive, dilated eye exam is required in order to identify DR and many other eye diseases, and that can’t be done on a smart phone with the current camera technology in existence today. Where a smart phone could play a role is also in the cloud delivery of results to care teams and to patients – for example, you could use your smart phone to pull test results down from the cloud via any browser,” Joanna Batstone, the VP and lab director of the IBM Research center in Australia that published the study, told MobiHealthNews in an email.

By Heather Mack | mobi health news

Image Credit: mobi health news

READ MORE

About Peter Coffaro 1104 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the medical device industry. As a District Sales Manager for Stryker Orthopaedics, Peter was responsible for managing and directing a regional sales force to achieve sales and profit goals within the Rocky Mountain region. Previously, he was the Director of Sales & Marketing for Amp Orthopedics. In this role, Peter was responsible for planning, developing, and leading all sales and marketing initiatives. Peter is a former orthopedic distributor in the Pacific Northwest. He has also worked with DePuy Orthopaedics as well as Zimmer, and held positions in sales, sales training, and sales management. Peter has an extensive background in organizational development, business development, sales management, negotiating and P&L management. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


*